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Hepatocyte Levels of CD73 Contribute to Mallory-Denk Body Formation
To the Editor:
Snider et al.1 reported low levels of CD73 in hepatitis C and
nonalcoholic steatohepatitis (NASH) livers, where Mallory-Denk
bodies (MDBs) formed. In a mouse model (C57BL), low levels of
CD73 developed when fed 3,5-diethoxycarbonyl-1,4-dihydrocoli-
dine (DDC) and MDBs formed. Thus, both human and mouse
livers with reduced levels of CD73 correlated with increased MDB
formation. Paradoxically, Snider et al.1 observed that CD732/2
mice fed DDC failed to form MDBs. They offer no mechanism to
explain this paradox. “If low levels of CD73 increase MDB forma-
tion, isn’t it logical to expect that, in the absence of CD73 in
CD732/2 mice, they would form even more MDBs?” They do
show that some of the CD732/2 mice fed DDC formed a lower
amount of high molecular weight (HMW) proteins and ubiquiti-
nated HMW proteins (their fig. 4D). The normal K8 blot, on the
other hand, was greatly increased by DDC feeding in the CD732/2
mice. This did not occur in the wild-type mice where MDBs were
formed. These paradoxical observations are hard to reconcile. One
explanation could be that low levels of CD73 somehow causes a
decrease in 26S proteasome activity. However, the absence of
CD73 does the opposite, that is, it prevents the loss of 26s protea-
some activity. MDBs form when a shift occurs in the formation of
the 26s proteasome. This shift is to the formation of the immuno-
proteasome.2,3 The shift to form the immunoproteasome is the
result of the response of interferon (IFN) sequence response
element on the UbD (FAT10 in humans) promoter stimulated by
IFNc and tumor necrosis factor alpha (TNFa).4 UbD is markedly
induced in the DDC mouse model of MBD formation.5 SAMe
prevents this DDC induction of UbD, MDB formation, and the
induction of immunoproteasome formation.3,5 UbD2/2 mice fed
DDC cannot form MDBs.6
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Reply:
We thank Dr. French for his comments and questions about
our study on the role of the ecto-nucleotidase CD73 in mouse
liver Mallory-Denk body (MDB) formation.1 CD73 is expressed
in multiple tissues, including the lung, heart, brain, kidney, liver,
and the immune system.2 Although formation of extracellular
adenosine is considered its primary function, CD73 also may act
in a number of other ways independent of its enzymatic role.3
As Dr. French pointed out, our findings that CD732/2 mice
are resistant to MDB formation is somewhat counterintuitive,
given our initial observation that the MDB-susceptible mouse
strain (C57BL/6J) is characterized by having lower CD73 mRNA
and protein levels under basal conditions compared to the
MDB-resistant C3H/He strain. However, we also showed that
after 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) treatment
there was a near complete loss of cell surface CD73 (AMPase)
activity, but only a 60% decrease in overall CD73 activity (meas-
ured biochemically after tissue lysis). This observation, together
with our findings of DDC-induced loss of plasma membrane
CD73 in isolated hepatocytes, illustrates the complex nature of
CD73 regulation in this model of liver injury. Therefore, the sub-
cellular distribution (organellar versus plasma membrane) and reg-
ulation (such as glycosylation changes and enzymatic activity) of
CD73 during hepatocellular injury are likely a more important
determinant of hepatocyte injury than the overall CD73 expression
levels.
Furthermore, the MDB resistance in CD732/2 mice also may
be immune-related, given the known major role of CD73 in regu-
lating inflammatory and immune responses.4 For example, in
absence of CD73 to catalyze the final and irreversible step in the
conversion of extracellular adenosine triphosphate (ATP) to adeno-
sine, the ATP levels in the vicinity of damaged and dying cells
may significantly increase. This can accelerate the clearance of
damaged cells by promoting phagocytosis by way of a number of
mechanisms.5 Altered purinergic signaling on other immune cell
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types, such as regulatory T cells,6 also may alter the course of liver
injury progression in CD732/2 mice.
In summary, resistance to MDB formation in CD732/2 mice
likely is related to a number of hepatocyte-intrinsic and -extrinsic
mechanisms. Generation of mice with targeted deletion of CD73
from specific cell types should help resolve many outstanding
questions pertaining to the functions of this enzyme in the liver.
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Vitamin D Levels in Patients With Chronic Hepatitis B
To the Editor:
We read with interest the article by Farnik et al.1 regarding the
low vitamin D levels in patients with chronic hepatitis B virus
(HBV). A remarkable finding was the inverse relationship between
serum vitamin D levels and HBV viral load.
A previous study in patients with chronic hepatitis C had also
shown that necroinflammatory activity as well fibrosis scores
were independently linked to low vitamin D levels.2 Because of
small cohort size, the researchers could not show an association
between serum vitamin D levels and fibrosis scores. However,
considering that necroinflammatory activity was not included in
statistical analysis in this study; we would like to point out that
high necroinflammatory activity may also explain the low vita-
min D levels in patients with HBV. Before drawing a definitive
conclusion, more details ought to be presented about this impor-
tant issue.
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Trends in Hepatitis C Treatment Uptake in the United States
To the Editor:
In May 2011, the United States Food and Drug Administra-
tion (FDA) approved the direct-acting antiviral (DAA) drugs
boceprevir (BOC) and teleprevir (TVR) to be used in combina-
tion with peginterferon and ribavirin (PEG/RBV) for genotype 1
(G1) chronic hepatitis C (HCV). These drugs offered improve-
ments in efficacy and reduced duration for some patients, benefits
somewhat compromised by increased adverse events and pill
burden.
Major increases in treatment uptake rates are required to impact
the growing burden of disease from HCV complications including
cirrhosis and hepatocellular carcinoma.1 However, it is not clear
whether HCV treatment uptake increased since the availability of
BOC and TVR. We surveyed prescription activity in the USA after
the FDA approval of BOC and TVR, using proprietary databases
(see online methods).
The impact of these medications on the total number of HCV
patients treated was small (Table 1). Over 80,000 patients were
Table 1. Prescription Rates for Hepatitis C Therapy
2008-2012
Year PEGalfa-2A PEGalfa-2B Telaprevir Boceprevir
2008 57,544 26,081 N/A N/A
2009 53,066 17,340 N/A N/A
2010 53,610 13,311 N/A N/A
2011 64,466 12,790 26,177 7,932
2012 52,656 11,596 36,801 14,787
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